Cargando…
A retrospective analysis of treatment‐related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia
This retrospective study examined the longitudinal hospital outcomes (costs adjusted for inflation, hospital days, and admissions) associated with the treatment of pediatric, adolescent, and young adult acute lymphoblastic leukemia (ALL). Patients between one and 26 years of age with newly diagnosed...
Autores principales: | Kaul, Sapna, Korgenski, Ernest Kent, Ying, Jian, Ng, Christi F., Smits‐Seemann, Rochelle R., Nelson, Richard E., Andrews, Seth, Raetz, Elizabeth, Fluchel, Mark, Lemons, Richard, Kirchhoff, Anne C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735779/ https://www.ncbi.nlm.nih.gov/pubmed/26714675 http://dx.doi.org/10.1002/cam4.583 |
Ejemplares similares
-
LINC00221 suppresses the malignancy of children acute lymphoblastic leukemia
por: Huang, Man, et al.
Publicado: (2020) -
Cost comparison by treatment arm and center‐level variations in cost and inpatient days on the phase III high‐risk B acute lymphoblastic leukemia trial AALL0232
por: DiNofia, Amanda M., et al.
Publicado: (2017) -
How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?
por: Pinchinat, Ashley, et al.
Publicado: (2022) -
The genomic landscape of teenage and young adult T‐cell acute lymphoblastic leukemia
por: Mansur, Marcela B., et al.
Publicado: (2021) -
Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia
por: Karol, Seth E., et al.
Publicado: (2020)